Co-Transplantation of Haploidentical Stem Cells and a Dose of Unrelated Cord Blood in Pediatric Patients with Thalassemia Major

被引:4
|
作者
Wang, Xiaodong [1 ]
Zhang, Xiaoling [1 ]
Yu, Uet [1 ]
Wang, Chunjing [1 ]
Yang, Chunlan [1 ]
Li, Yue [1 ]
Li, Changgang [1 ]
Wen, Feiqiu [1 ]
Li, Chunfu [2 ,3 ]
Liu, Sixi [1 ]
机构
[1] Shenzhen Childrens Hosp, Dept Hematol & Oncol, Shenzhen, Peoples R China
[2] Taixin Hosp, Nanfang Chunfu Childrens Inst Hematol & Oncol, Dongguan, Peoples R China
[3] Southern Med Univ, Nanfang Hosp, Dept Pediat, Guangzhou, Peoples R China
关键词
haploidentical stem cell transplantation; cord blood transplant; thalassemia;
D O I
10.1177/0963689721994808
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Allogeneic stem cell transplantation is a cure for patients suffering from thalassemia major (TM). Historically, patients were limited by the selection of donors, while the advancement of haploidentical stem cell transplantation (haplo-SCT) has greatly expanded the donor pool. However, the outcomes of haplo-SCT in TM recipients vary between different programs. In this study, we retrospectively studied 73 pediatric TM patients (median age, 7 years; range, 3 to 14 years) who underwent haplo-cord transplantation. Both the estimated overall survival and transfusion-free survival were 95.26% (CI 95.77% to 96.23%). Neither primary nor secondary graft failures were observed. The median follow-up period was 811 days (range, 370 to 1433 days). Median neutrophil and platelet engraftment times were 22 days (range, 8 to 48 days) and 20 days (range, 8 to 99 days), respectively. Acute graft-versus-host disease (aGVHD) was observed in 52% of patients and of these, 25% developed grade III to IV aGVHD. Cord blood engraftment was associated with delayed immune recovery and increased aGVHD severity. Viral DNAemia occurred in a relatively high proportion of patients but only 7% of patients developed CMV disease, while another 7% of patients had post-transplantation lymphoproliferative disorder. Long-term complication outcomes were good. Only one patient developed extensive chronic GVHD. No surviving patients were reliant on blood transfusion by the time this manuscript was submitted. This is one of the largest studies on the outcomes of pediatric TM patients who received stem cell transplantations from alternative donors. The haplo-cord program is safe and practical for TM patients that do not have matched donors.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Complementary Transplantation with Haploidentical Stem Cells and Unrelated Cord Blood in Thalassemia Major
    Li, Chunfu
    He, Yuelin
    Wu, Xuedong
    Feng, Xiaoqin
    Liao, Jianyun
    Pei, Fuyu
    Peng, Zhiyong
    Liu, Huaying
    Leung, Wing
    [J]. BLOOD, 2016, 128 (22)
  • [2] Complementary Transplantation with Haploidentical Stem Cells and Unrelated Cord Blood for Leukemia and Thalassemia
    Li, Chunfu
    He, Yuelin
    Wu, Xuedong
    Feng, Xiaoqin
    Liao, Jianyun
    Peng, Zhiyong
    Pei, Fuyu
    Liu, Huaying
    Leung, Wing
    [J]. BLOOD, 2016, 128 (22)
  • [3] CO-TRANSPLANTATION OF MESENCHYMAL STEM CELLS AND HEMATOPOIETIC STEM CELLS IN β-THALASSEMIA PATIENTS
    Ghavamzadeb, A.
    Valizadeh, N.
    Alimoghaddam, K.
    Karimi, A.
    Baboush, G.
    Bashtar, M.
    Shamshiri, A. R.
    Jalili, M.
    Mosavi, A. S.
    Shahriari, Z.
    Basirpanab, S.
    Khalilvand, S.
    Chardouli, B.
    Khatami, F.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (02) : 48 - 48
  • [4] Liver fibrosis alleviation after co-transplantation of hematopoietic stem cells with mesenchymal stem cells in patients with thalassemia major
    Ardeshir Ghavamzadeh
    Masoud Sotoudeh
    Amir Pejman Hashemi Taheri
    Kamran Alimoghaddam
    Hossein Pashaiefar
    Mahdi Jalili
    Farhad Shahi
    Mohammad Jahani
    Marjan Yaghmaie
    [J]. Annals of Hematology, 2018, 97 : 327 - 334
  • [5] Liver fibrosis alleviation after co-transplantation of hematopoietic stem cells with mesenchymal stem cells in patients with thalassemia major
    Ghavamzadeh, Ardeshir
    Sotoudeh, Masoud
    Taheri, Amir Pejman Hashemi
    Alimoghaddam, Kamran
    Pashaiefar, Hossein
    Jalili, Mahdi
    Shahi, Farhad
    Jahani, Mohammad
    Yaghmaie, Marjan
    [J]. ANNALS OF HEMATOLOGY, 2018, 97 (02) : 327 - 334
  • [6] UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION FOR CHILDREN WITH β-THALASSEMIA MAJOR
    Shah, S. A.
    Beniwal, S. K.
    Shah, K. M.
    Patel, K. A.
    Patel, K. M.
    Shah, P. M.
    [J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (02) : S258 - S259
  • [7] Successful unrelated cord blood transplantation in a child with β-thalassemia major
    Jaing, TH
    Hung, IJ
    Yang, CP
    Lin, TY
    Chow, R
    Hsieh, SI
    [J]. JOURNAL OF TROPICAL PEDIATRICS, 2005, 51 (02) : 122 - 124
  • [8] Unrelated umbilical cord blood transplantation for an infant with β-thalassemia major
    Hall, JG
    Martin, PL
    Wood, S
    Kurtzberg, J
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2004, 26 (06) : 382 - 385
  • [9] Co-transplantation of parental mesenchymal stem cells to improve outcome of cord blood transplantation in children
    Bernardo, M. E.
    Ball, L.
    Cometa, A.
    Zecca, M.
    Giorgiani, G.
    Maccario, R.
    Barberi, W.
    Comoli, P.
    Bonetti, F.
    Le Blanc, K.
    Roelofs, H.
    Egeler, M.
    Fibbe, W.
    Locatelli, F.
    [J]. BONE MARROW TRANSPLANTATION, 2007, 39 : S52 - S52
  • [10] CO-TRANSPLANTATION OF HAPLOIDENTICAL TRANSPLANTATION AND UMBILICAL CORD BLOOD UNIT PROVIDE SIGNIFICANT SURVIVAL BENEFIT FOR PATIENTS WITH LEUKEMIA
    Sun, A.
    Wang, J.
    Yang, S.
    Zhou, H.
    Qiu, H.
    Tang, X.
    Jin, Z.
    Han, Y.
    Fu, C.
    He, G.
    Ma, X.
    Wu, D.
    [J]. HAEMATOLOGICA, 2014, 99 : 170 - 170